510(k) K220193
K220193 is an FDA 510(k) premarket notification submitted by Becton, Dickinson And Company for the device "BD MAX Enteric Parasite Panel". The FDA issued a decision of Substantially Equivalent on Aug 19, 2022. The device falls under product code PCH (Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System), a Class II device regulated under 21 CFR 866.3990. Becton, Dickinson And Company has 330 other 510(k) clearances on record.
Clearance details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- Aug 19, 2022
- Date Received
- Jan 24, 2022
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device classification
- Device Name
- Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System
- Device Class
- Class II
- Regulation Number
- 866.3990
- Review Panel
- MI
- Submission Type
- 510(k)
A gastrointestinal pathogen panel multiplex nucleic acid assay is a qualitative in vitro diagnostic device intended to simultaneously detect and identify multiple gastrointestinal microbial nucleic acids extracted from human stool specimens. The detection and identification of a specific gastrointestinal microbial nucleic acid from individuals exhibiting signs and/or symptoms of gastrointestinal infection aids in the diagnosis of gastrointestinal infection when used in conjunction with clinical evaluation and other laboratory findings.
Need the full FDA record for Becton, Dickinson And Company? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.